Showing results (1041-1050 of 2,063) with videos related to

Sort By:
Pageof 207
Brachytherapy|June 24, 2019
A skin dose prediction model based on in vivo dosimetry and ultrasound skin bridge measurements during intraoperative breast radiation therapyN Patrik Brodin, Keyur J Mehta, Amar Basavatia, et al.
Brachytherapy|June 16, 2019
Moving incision for covert breast-conserving surgery may prevent early wound complications in brachytherapy-based partial-breast irradiationKazuhiko Sato, Hiromi Fuchikami, Naoko Takeda, et al.
Brachytherapy|October 16, 2019
Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: Evidence from the Department of Veterans AffairsAlexander N Slade, Bassam Dahman, Michael G Chang
Brachytherapy|April 24, 2022
Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancerYu Ozawa, Yasuto Yagi, Ken Nakamura, et al.
Brachytherapy|March 26, 2022
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histologyChristopher W Smith, Taylor Marcus, Douglas Hoover, et al.
Brachytherapy|January 26, 2022
Clinical outcomes and dosimetric predictors of toxicity for re-irradiation of vaginal recurrence of endometrial cancerLarissa J Lee, Gabriela M Alban, Teresa Cheng, et al.
Brachytherapy|September 30, 2021
Safety and efficacy of GammaTile intracranial brachytherapy implanted during awake craniotomyShearwood McClelland, Ulysses G Gardner, Yi Le, et al.
Brachytherapy|September 30, 2021
Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancerDaniel Gorovets, Margaret Hopkins, Marisa Kollmeier, et al.
Brachytherapy|March 21, 2022
Reirradiation for recurrent head and neck carcinoma using high-dose-rate brachytherapy: A multi-institutional studyHideya Yamazaki, Koji Masui, Gen Suzuki, et al.
Brachytherapy|February 6, 2022
Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancerNeal Andruska, Jeff M Michalski, Ruben Carmona, et al.
Pageof 207